Skip to main
ACOG

ACOG Stock Forecast & Price Target

ACOG Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alpha Cognition is a biopharmaceutical company with a strong focus on the commercial manufacturing and sales of its lead drug, ZUNVEYL. Their current financial results and forecasts show strong potential for revenue growth and net profitability, with a 12-month price objective of $18 per share. However, potential risks include challenges in achieving sales traction and market uptake for ZUNVEYL, as well as setbacks in clinical testing and potential dilution risk in the medium to long-term.

Bears say

Alpha Cognition is a biopharmaceutical company currently conducting or planning to initiate multiple clinical trials for its lead product, ZUNVEYL, which is expected to provide important real-world evidence and drive future commercial opportunities. Additionally, the company recently settled a payment agreement with Galantos Pharma, adding to its stable financial position, and appointed a new director with significant experience in the biopharmaceutical industry and a history of successful financial and operational leadership. These positive developments support the company's potential for long-term growth, making Alpha Cognition a promising investment opportunity.

ACOG has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alpha Cognition Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alpha Cognition Inc (ACOG) Forecast

Analysts have given ACOG a Strong Buy based on their latest research and market trends.

According to 4 analysts, ACOG has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alpha Cognition Inc (ACOG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.